Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02337491
Title Pembrolizumab +/- Bevacizumab for Recurrent GBM
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

glioblastoma

gliosarcoma

high grade glioma

Therapies

Pembrolizumab

Bevacizumab + Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.